Home » Newsletters » BioWorld Asia

BioWorld Asia

Aug. 19, 1998

View Archived Issues

Xenova, With Funds To Last Through 1998, Seeks Investors

British Biotech Woes Push UK To Consider Tighter Industry Controls

MorphoSys Changes Partners; Plans Public Offering In '98

Canada To Involve Nation In Debate On Biotech Issues

Display Systems Biotech Seeks Higher US Profile

Amrad Suspends Clinical Trial Of Reformulated Anesthetic

Research Institutes Spawn Many Australian Biotech Firms

French Study Shows Urokinase May Inhibit Growth Of Cancer

Clal Invests $10M In D-Pharm; Takes First Step Into Biotech

Appligène Reports 2Q Sales Increased Over Last Year

European Consumer Group Wants Aggressive GMO Food Labeling

D-Pharm Gets US Patent For Neuroprotective Agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...